Actively Recruiting
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
Led by Ferring Pharmaceuticals · Updated on 2025-08-20
500
Participants Needed
1
Research Sites
353 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
CONDITIONS
Official Title
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.
You will not qualify if you...
- No exclusion criteria because data are collected under conditions of use in daily practice.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ferring Investigational Site
Omitama, Ibaraki, Japan
Actively Recruiting
Research Team
G
Global Clinical Compliance
CONTACT
G
Global Clinical Compliance
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here